Why I’d buy AstraZeneca shares in September

AstraZeneca shares dropped last week. Suraj Radhakrishnan analyses if this presents a buying opportunity in the long term.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) shares have rebounded well after their 25% fall in March 2021. This came after the share price hit all-time highs in mid-2020. Despite the 22% increase in the last six months, at 8,565p, AstraZeneca shares are down 2.2% in the last week. I think this drop offers an excellent buying opportunity for my long-term portfolio.  

Pharma giant

The pharmaceutical company gained a lot of prominence during the pandemic after pricing its Covid-19 vaccine considerably lower than competitors like Pfizer and Moderna. Its efforts alongside oxford University to rollout the vaccine is a success story. But I think the larger picture lies in the steady growth the company has made since 2012. Historically, the company focusses R&D in oncology, cardiovascular, metabolic, and respiratory disease, and not on vaccines.

Its recent 2021 half-yearly (H1) report suggests to me that AstraZeneca is reaping the rewards of these R&D efforts. Growing at an annual rate of 5.9% since 2017, the £130bn industry leader looks like an attractive defensive option for steady returns for my long-term portfolio.

Focus on the future

The company has been making big strides in the research of cancer treatments and immune support medications. As visible in the H1 results, total revenue was up 18% at $15.5bn with a second-quarter growth of 25%. As a result, operating profits in H1 2021 was up 20% to $3.02bn. But, this growth is not just a result of the boost in sales from the Covid-19 vaccine. This is evident when I look at the earnings per share figures, which stand at $2.53 of which just $0.04 was from vaccine sales.

Revenue from oncology and cardiovascular, renal, & metabolism (CVRM) grew 15% and 16% respectively. These divisions served as the largest revenue streams for the company despite the increase in vaccine sales.    

A sizeable portion of sales also come from emerging markets and newly approved medicines under the AstraZeneca label. Emerging market sales grew 21% in H1 2021 with a 28% jump in cardiovascular and renal care treatments. Over the last three years, more than half of the top-selling items in the company were newly developed medicines.

AstraZeneca share price concerns

The pharma company’s shares come with some concerns. New drugs and medical patents have a shelf-life. Mass-produced, generic alternatives eventually find a way into the market, which could cause a drop-off in sales.

The current forward price-to-earnings (P/E) multiple of 40.9 and PE/growth (PEG) ratio of 1.42 suggests inflated valuations. But, factoring in the projected growth figures of 2022 of 28% could bring down the PEG value below one. Moving averages also suggest a jump in share prices in the short term.

Subsequently, analysts expect 2020’s cash-in-hand of $3.9bn to rise to $7.7bn by 2022. The company supports a progressive dividend policy and the current yield of 2.36% could double in the future.

Factoring in projected growth and the pandemic-driven all-time high of 9,187p, I think AstraZeneca’s shares could break through this ceiling in the next 12 months. Of course, all this is predicated on revenue meeting forecasted levels. But, I think the company is well-set to achieve targets.

Overall, AstraZeneca’s shares earns a spot on my FTSE 100 watchlist and I think it is a stock that could deliver steady returns over the next decade.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Suraj Radhakrishnan has no position in any of the shares mentioned. The Motley Fool UK has recommended Moderna Inc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »